BeOne Medicines Ltd
200 hedge funds and large institutions have $6.68B invested in BeOne Medicines Ltd in 2024 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 72 increasing their positions, 66 reducing their positions, and 24 closing their positions.
31% more call options, than puts
Call options by funds: $18.6M | Put options by funds: $14.2M
9% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 66
0.03% more ownership
Funds ownership: 3.72% → 3.75% (+0.03%)
2% less funds holding
Funds holding: 205 → 200 (-5)
8% less capital invested
Capital invested by funds: $7.3B → $6.68B (-$615M)
17% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 24
20% less funds holding in top 10
Funds holding in top 10: 10 → 8 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$58.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$38M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$9.79M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$6.95M |
| 5 |
LCAM
Long Corridor Asset Management
Hong Kong
|
+$6.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$15.6M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$14.6M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$10.1M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$8.55M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$8.08M |
ONC Hedge Fund Activity: Q2 2024 in Review
200 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q2 2024, worth a combined $6.68B — down 8.4% from $7.3B a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ONC and 20 opened new positions — a net loss of 4 holders — while 66 trimmed existing stakes and 72 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $58.8M. The largest seller was Artal Group, cutting an estimated $15.6M.
- 200 institutional investors held BeOne Medicines Ltd (ONC) as of Q2 2024, down from 205 in Q1 2024.
- Funds reported $6.68B of BeOne Medicines Ltd stock for Q2 2024, down 8.4% quarter-over-quarter.
- 20 funds opened new BeOne Medicines Ltd positions in Q2 2024 and 24 closed out, a net change of -4 holders.
- The largest BeOne Medicines Ltd buyer in Q2 2024 was Point72 Asset Management, an estimated $58.8M added.
- The largest BeOne Medicines Ltd seller in Q2 2024 was Artal Group, an estimated $15.6M sold.
Based on aggregated 13F filings for Q2 2024.